Activation of host antitumoral responses by cationic lipid/DNA complexes

被引:31
作者
Bramson, JL [1 ]
Bodner, CA [1 ]
Graham, RW [1 ]
机构
[1] Inex Pharmaceut Corp, Burnaby, BC, Canada
关键词
cationic liposome; inflammation; gene therapy;
D O I
10.1038/sj.cgt.7700143
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A model of lipoplex-induced peritonitis was used to characterize the inflammatory response to cationic lipid:DNA lipoplexes with respect to activation of host antitumoral effector mechanisms. Three different cationic lipids were used in these studies: N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N-(1-[2,3-dioleoyloxy]propyl)-N,N,N-trimethylammonium chloride (DOTAP), and N-(1-[2,3-dioleyloxy]propyl)-N,N,N-trimethylammonium chloride (DOTMA). The DODAC and DOTMA lipoplexes exhibited similar transfection properties in vitro, whereas the DOTAP lipoplexes transfected quite poorly in all cell lines tested. Intraperitoneal injection of cationic lipoplexes into immunocompetent mice resulted in a profound infiltration of inflammatory cells, secretion of interferon-gamma, and increased natural killer activity within the peritoneal cavity. Both DODAC and DOTMA lipoplexes produced similar inflammatory responses, lasting at least 5 days. The inflammation induced by DOTAP lipoplexes peaked by day 3 and resolved to near-control levels by day 5. These data indicate that although cationic lipid DNA complexes may differ in their inflammatory properties, the natural killer activation and interferon-gamma secretion that follow lipoplex administration should provide a functional adjuvant for cancer gene therapies that benefit from immunostimulation.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 29 条
[1]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[2]  
BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
[3]   Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases [J].
Blezinger, P ;
Freimark, BD ;
Matar, M ;
Wilson, E ;
Singhal, A ;
Min, W ;
Nordstrom, JL ;
Pericle, F .
HUMAN GENE THERAPY, 1999, 10 (05) :723-731
[4]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[5]   Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12 [J].
Bramson, J ;
Hitt, M ;
Gallichan, WS ;
Rosenthal, KL ;
Gauldie, J ;
Graham, FL .
HUMAN GENE THERAPY, 1996, 7 (03) :333-342
[6]  
Brittenden J, 1996, CANCER-AM CANCER SOC, V77, P1226, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1226::AID-CNCR2>3.0.CO
[7]  
2-G
[8]   CYTOKINE GENE-TRANSFER IN TUMOR-INHIBITION AND TUMOR-THERAPY - WHERE ARE WE NOW [J].
COLOMBO, MP ;
FORNI, G .
IMMUNOLOGY TODAY, 1994, 15 (02) :48-51
[9]  
Egilmez NK, 1996, GENE THER, V3, P607
[10]   Anti-inflammatory activity of cationic lipids [J].
Filion, MC ;
Phillips, NC .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (03) :551-557